The guidance describes how FDA plans to work with applicants and sponsors to achieve expedited development and rapid review of new drugs or biological products intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs for the condition. A sponsor or applicant seeking to have a drug or biological product designated as one in a fast track drug development program may submit a request for fast track designation as an amendment to an IND or as a supplement to an application. After FDA makes a fast track designation, the sponsor or applicant may submit a pre-meeting package which may include additional information supporting a request to participate in certain fast track programs.
The adjustment in burden from 14,780 to 15,700 hours is the result of an increase in the number of designation requests and premeeting packages submitted over the past three years.
On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).
The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control number;
If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.